284 results about "Virus strain" patented technology

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV-75 and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-75, has the preservation number of CCTCC NO: V2024114, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.

The invention discloses an hMPV virus fusion protein F variant, an mRNA vaccine and application of the hMPV virus fusion protein F variant and the mRNA vaccine. The hMPV fusion protein F variant has amino acid residue difference on one or more sites relative to an hMPV fusion protein F with the login number of AGJ74096.1 in a GeneBank database, wherein the amino acid sequence of the hMPV fusion protein F variant is shown as SEQ ID NO: 1 or SEQ ID NO: 2. The mRNA vaccine designed based on the hMPV fusion protein F variant can induce a strong specific antibody reaction, the durability of the antibody in vivo is strong, the induced antibody can well neutralize an hMPV strain, the amplification of the hMPV in the lung is controlled, and the immune response of the hMPV in the lung is inhibited. Therefore, the specific antibody induced by the mRNA vaccine provides an effective basis for preventing hMPV virus infection related diseases and developing multi-combined vaccines.

The invention discloses a separation method of a bovine ephemeral fever virus, the obtained bovine ephemeral fever virus and application of the bovine ephemeral fever virus. Belongs to the technical field of bovine ephemeral fever virus separation. The invention aims to provide an efficient and rapid method for separating the bovine ephemeral fever virus. The invention provides a method for separating bovine ephemeral fever virus, which comprises the following steps: inoculating a bovine anticoagulant sample to KC cells for culture, harvesting virus, inoculating to grow into monolayer BHK-21 cells, and carrying out passage to obtain passage cells with cytopathy of the first generation; the virus strain can also be used for screening, preparing and detecting a bovine ephemeral fever virus antibody and preparing a bovine ephemeral fever virus infected animal model.

The invention provides a recombinant Marek's disease virus co-expressing a Newcastle disease virus F gene and an infectious bursal disease virus supervirulent strain VP2 gene and application thereof, and belongs to the field of genetic engineering vaccines. According to the invention, by using a recombinant cloning technology, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an infectious bursal disease virus super virulent strain VP2 gene is inserted into a spacer region between Marek's disease virus genome UL45 and UL46 genes; according to the method, a recombinant cosmid is constructed and obtained, wherein a Newcastle disease virus F gene and an infectious bursal disease virus super virulent strain VP2 gene expression framework are inserted between Marek's disease virus genome UL45 and UL46 genes, and a recombinant virus C20101 strain co-expressing the Newcastle disease virus F gene and the infectious bursal disease virus super virulent strain VP2 gene is rescued and obtained by the recombinant cosmid. The vaccine prepared from the recombinant Marek's disease virus strain provided by the invention can prevent Newcastle disease, chicken infectious bursal disease and Marek's disease at the same time, and has a good market application prospect.

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV DQ and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-DQ, has the preservation number of CCTCC NO: V2024113, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.

The invention belongs to the field of veterinary biotechnology detection, and particularly relates to a hybridoma cell strain and a monoclonal antibody for detecting or identifying MDV-1 and application of the hybridoma cell strain and the monoclonal antibody. The hybridoma cell strain MDV-1Mab-pp38-E2 is obtained through screening by taking pp38 protein of MDV-1 as immunogen, the preservation number is CCTCC NO: C202501, the monoclonal antibody generated by the hybridoma cell strain can recognize I-type chicken Marek's disease virus strains with different serum, and the monoclonal antibody can be used for identifying the type I chicken Marek's disease virus strains with different serum types. The kit has good specificity and sensitivity and can be used for exogenous virus detection of the serum type I chicken Marek's disease virus in poultry virus live vaccines without cross reaction with serum type II chicken Marek's disease virus, serum type III chicken Marek's disease virus, chicken egg drop syndrome virus (EDSV) and other common poultry disease viruses, and the kit has good specificity and sensitivity and can be applied to exogenous virus detection of the serum type I chicken Marek's disease virus in poultry virus live vaccines. The kit can also be used for clinical identification, virus content determination and epidemiological investigation of serotype I chicken Marek's disease virus.

The invention relates to the technical field of biological medicine, in particular to a hepatitis A inactivated vaccine and a preparation method thereof. Comprising the following steps: cell amplification, virus culture, virus harvesting, cell disruption, ultrafiltration concentration, inactivation, purification and finished product obtaining. The virus culture comprises the following steps: separating from excrement of a hepatitis A patient and carrying out adaptive passage to obtain a virus strain; adding a carrier into a bioreactor, sterilizing for later use, inoculating a virus strain into a collected cell suspension, and transferring into the bioreactor for culturing; the cell disruption step comprises the following steps: carrying out ultrasonic oscillation on a collected virus harvesting liquid to obtain a cell disruption liquid; trichloromethane is added for extraction and centrifugation, and supernatant virus liquid is collected; the invention provides a preparation method of a hepatitis A inactivated vaccine, which is used for preparing the efficient, safe and stable hepatitis A inactivated vaccine by optimizing virus culture and inactivation processes. The method has the advantages of high virus yield and low production cost, and is suitable for large-scale production and application.

The invention provides a novel three-antigen HSV-2 adjuvant subunit vaccine as well as a preparation method and application thereof. The vaccine comprises herpes simplex virus recombinant protein and a composite adjuvant, the herpes simplex virus recombinant protein comprises extracellular domains of three proteins, namely HSV-2gE, gD and gC, wherein the amino acid sequences of the extracellular domains of the HSV-2gE, the gD and the gC are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; and the composite adjuvant is composed of CpG oligodeoxynucleotide and QS-21. Experiments prove that by adding the composite adjuvant composed of CpG oligodeoxynucleotide and QS-21, the immunogenicity, in-vivo protectiveness, virus removal and other immune functions of the HSV-2 subunit vaccine can be remarkably improved; meanwhile, the vaccine is a cross immune protection vaccine of an HSV-2 virus strain and an HSV-1 virus strain.

The invention discloses a genetically engineered virus strain of an African swine fever virus, and in a genome of the genetically engineered virus strain, a D250R gene is an inactivated gene. The microbial preservation number of a parent strain for preparing the genetic engineering virus strain is CCTCC (China Center For Type Culture Collection) NO: V 202318, and the GenBank accession number of a genomic sequence of the strain is OQ504956.1. The invention also discloses a preparation method of the genetically engineered virus strain, a vaccine composition containing the genetically engineered virus strain, a preparation method of the vaccine composition, and application of the genetically engineered virus strain in preparation of a preparation for preventing African swine fever. The genetically engineered virus strain is good in safety and immune effectiveness, and has the potential of preparing clinically applied vaccines.

The invention discloses a Newcastle disease vaccine strain with high antibody escape ability and a modification method thereof, the cell strain is preserved in China General Microbiological Culture Collection Center on January 19, 2024, the address of the preservation unit is CGMCC No.45870, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the classification name of the strain is Newcastle disease virus strain. The recombinant NDV vaccine strain has the same antigen site as the current NDV gene VII type epidemic strain and has the efficient proliferation efficiency superior to that of a classical vaccine strain La Sota, the thermal stability of the NDV vaccine strain is improved by the constructed recombinant vaccine strain, and the cost of vaccine cold-chain transportation is reduced.

The application discloses an isolation method of bovine epidemic fever virus and the bovine epidemic fever virus obtained by the method and application of the bovine epidemic fever virus, and belongs to the technical field of bovine epidemic fever virus isolation. The application aims to provide an efficient and rapid method for isolating bovine epidemic fever virus. The application provides the isolation method of the bovine epidemic fever virus, wherein the anticoagulated blood sample of a bovine is inoculated on KC cells for culture, the virus is harvested, the BHK-21 cells are inoculated to grow into a monolayer, and the first generation of passage cells with cytopathic effect is obtained by passage. The virus strain can also be used for screening, preparation and detection of bovine epidemic fever virus antibodies, and for preparation of an animal model infected by the bovine epidemic fever virus.

The invention belongs to the field of biomedicine, and particularly discloses a nasal spray influenza vaccine as well as a preparation method and application thereof. The invention provides a nasal spray influenza vaccine. Fusion protein in the nasal spray influenza vaccine comprises influenza virus strain HA protein or fragments thereof, influenza virus protein epitopes and ferritin. The adjuvant may be a CpG1009 adjuvant to enhance humoral and cellular immunity. A vaccine composed of the fusion protein and a novel CpG adjuvant can induce generation of a strong challenge protection effect.

The application discloses a disease transmission link prediction method and system based on a dynamic hypergraph neural network, aiming to comprehensively depict virus transmission paths and risk levels from multiple dimensions. First, data is collected from a gene database, mobile device logs and clinical texts, virus variation characteristics, population contact relationships and symptom semantic information are extracted respectively, and a dynamic hypergraph that integrates virus strain nodes, individual nodes and regional nodes is constructed. The hyperedge is defined according to molecular similarity, space-time contact and semantic overlap, and the weight is dynamically adjusted according to the transmission intensity of the infectious disease. A multi-modal hypergraph neural network with variation perception is introduced to jointly model and adaptively fuse multiple types of hyperedges and multi-scale features, output node propagation embedding vectors and predict potential transmission chains, perform prevention and control responses, and realize real-time deployment and feedback loop in an edge-cloud collaborative manner, ensuring efficient and accurate infectious disease transmission modeling and intervention control while ensuring data privacy.

The invention discloses a porcine reproductive and respiratory syndrome virus NADC30 strain SCqq strain, an inactivated vaccine and application, and belongs to the technical field of veterinary medicine. The SCqq strain is preserved in the China Center for Type Culture Collection, the preservation address is Wuhan University, Wuchang District, Wuhan City, Hubei Province, the preservation number is CCTCC NO: V202486, and the preservation time is September 29, 2024. According to the invention, a porcine reproductive and respiratory syndrome virus NADC30 strain SCqq strain is screened, and an inactivated vaccine prepared from the virus strain is high in immunogenicity, safe and reliable, has a very good immune protection effect on porcine reproductive and respiratory syndrome virus NADC30 infection, can induce an organism to generate a high-level antibody, and achieves 100% virulent virus attack protection.

The invention relates to the technical field of viruses, in particular to a construction method and application of an African swine fever virus strain. According to the invention, the three virulence genes MGF110-9L, EP402R and I73R of the African swine fever virus are taken as targets for the first time to construct a virus strain with deletion of the three virulence genes, and the virus strain is found to be capable of effectively reducing the virus toxicity but retaining better immunogenicity, can improve the immunity of an organism to the African swine fever virus, and has a relatively great application prospect.

The invention discloses a disease transmission link prediction method and system based on a dynamic hypergraph neural network, and aims to comprehensively describe a virus transmission path and a risk level from multiple dimensions. The method comprises the following steps: firstly, collecting data from a gene database, a mobile equipment log and a clinical text, respectively extracting virus variation characteristics, a crowd contact relationship and symptom semantic information, and constructing a dynamic hypergraph fusing virus strain nodes, individual nodes and region nodes; the hyperedge is defined according to molecular similarity, space-time contact and semantic overlap, and the weight is dynamically adjusted along with the infectious disease transmission intensity. A multi-modal hypergraph neural network of variation perception is introduced, joint modeling and adaptive fusion are performed on multi-type hyperedge and multi-scale features, a node propagation embedded vector is output, a potential propagation chain is predicted, prevention and control response is executed, and real-time deployment and feedback closed loop are realized in an edge-cloud cooperation mode. And efficient and accurate infectious disease transmission modeling and intervention control are completed on the premise of ensuring data privacy.

The invention provides an application of nigericin in preparation of an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drug, and belongs to the technical field of antiviral drugs. Experimental results show that the nigericin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the nigericin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

The invention discloses an antigen binding fragment for resisting a sarbecovirus coronavirus, the antigen binding fragment comprises a complementarity determining region, the complementarity determining region comprises a CDR3, and the amino acid sequence of the CDR3 is shown as SEQ ID NO.3. The invention also discloses an antigen binding fragment for resisting the sarbecovirus coronavirus. The invention also discloses an antibody which comprises the antigen binding fragment. The invention also discloses a biological material related to the antigen binding fragment or the antibody, a method for preparing a single-chain antibody, a detection or diagnosis reagent and a pharmaceutical composition. The antigen binding protein and the antibody provided by the invention are broad-spectrum antibodies aiming at coronavirus, not only can effectively neutralize various variants, but also have high affinity and lasting effectiveness, can improve the ability of resisting newly appearing sbecovirus coronavirus strains, and are beneficial to improving the treatment effect and reducing the severe case rate.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

The invention belongs to the field of biomedicine, and particularly discloses an influenza nanoparticle vaccine as well as a preparation method and application thereof. The fusion protein containing the influenza virus strain HA protein or the fragment thereof, the influenza virus protein epitope and the ferritin can be used as an antigen to induce an immune response effect aiming at influenza viruses, and a vaccine formed by matching the fusion protein with an MF59 adjuvant can be used for inducing to generate a relatively strong challenge protection effect and has a relatively good cross protection effect.

The invention belongs to the technical field of biology, and particularly relates to a 3D protein mutated O-type foot-and-mouth disease recombinant virus strain as well as construction and application thereof. The 403th methionine of the O-type foot and mouth disease virus 3D protein is mutated into alanine, the recombinant virus strain rFMDV-M403A with the mutated O-type foot and mouth disease virus 3D protein is successfully constructed and saved by using a reverse genetic technology, and amino acid of the recombinant virus strain can be stably mutated in a passage process; the growth speed of the mutant strain is slower than that of a wild strain, and the virus titer is remarkably reduced; in an individual experiment, neonatal mouse infection shows that the mutant strain can improve the survival rate of neonatal mice, and the virus load and tissue lesion in the liver are remarkably reduced. The attenuated foot-and-mouth disease recombinant virus strain provided by the invention provides important significance for deep understanding of a foot-and-mouth disease virus pathogenic mechanism and a prevention and control strategy, and also provides an important theoretical basis for further development of a foot-and-mouth disease genetic engineering vaccine.

This document provides details regarding the construction of a recombinant African swine fever virus (ASFV) live attenuated vaccine for the prevention of African swine fever (ASF) caused by various viral strains of ASFV such as the highly virulent Georgia 2007 isolate (“ASFV-G”). Exemplary vaccines comprise an ASFV-GΔI177l modified virus, i.e., a recombinant ASFV-G modified by deletion of a portion of the I177L ORF such that the I177L gene is rendered non-functional.

The invention provides a Garlu virus attenuated strain and application thereof, and relates to the field of virology and biological medicine. According to the invention, the screened Garlu virus attenuated strain is a natural attenuated strain derived from a tick sample, can grow in Vero cells, has the titer of more than or equal to 107 TCID50 / mL, does not have clinical pathogenicity to an immunodeficient host, and is safe; after the attenuated strain is used as an immunogen for pre-intervention, infection of a lethal virus strain can be avoided, the survival rate is increased to 100%, adverse effects on growth and life of experimental animals are avoided, particularly, a host can be stimulated to generate humoral immunity and cellular immunity at the same time, and the survival rate of the experimental animals is improved. And moreover, broad-spectrum cross-protection efficacy can be generated on Bandavirus lethal virus strains, and a foundation is laid for improvement of research on Bandavirus live vaccines such as the Colu virus and the like.

The invention provides an L protein mutated recombinant foot-and-mouth disease virus strain and application thereof in vaccine preparation, and belongs to the technical field of biological medicine. Firstly, it is found that overexpression of CISD2 protein in host cells can inhibit FMDV replication, and an inhibition mechanism is analyzed, specifically, the CISD2 inhibits FMDV replication by inhibiting expression of L protein, especially inducing degradation of the L protein through a proteasome pathway. The invention also identifies a key site for degrading the L protein by the CISD2 protein, the recombinant foot-and-mouth disease virus with the mutated key amino acid site of the L protein is successfully constructed and rescued by introducing amino acid mutation of the key site into the L protein by utilizing a reverse genetic technology, the capabilities of degrading the L protein and inhibiting FMDV replication by the CISD2 protein are eliminated, the virus titer is improved, and the recombinant foot-and-mouth disease virus can be used for preparing the recombinant foot-and-mouth disease virus with the mutated key amino acid site of the L protein. The strain has good production performance and can be used for preparing recombinant foot-and-mouth disease virus strains and recombinant vaccine strains.

The present invention relates to a viral strain derived from a human metapneumovirus (hMPV) strain having a genomic sequence represented by sequence SEQ ID NO: 1 wherein the genomic sequence comprises the following genetic modifications: (i) inactivating an endogenous gene encoding an SH protein and / or a G protein, and (ii) the presence of an exogenous sequence encoding at least one extracellular domain of an F protein of a human respiratory syncytial virus (hRSV), the domain is of a wild type or mutant.

The invention relates to the technical field of biological detection, and particularly discloses an ELISA kit for detecting a neutralizing antibody of a severe fever with thrombocytopenia syndrome virus and an application method of the ELISA kit. The ELISA kit comprises an ELISA plate on which SFTSV receptor LRP1 protein is fixed, and an enzyme-labeled SFTSV Gn-8M, wherein the SFTSV receptor LRP1 protein is fixed on the ELISA plate; the SFTSV Gn-8M is an SFTSV membrane protein Gn mutant designed by the invention, and can be specifically combined with an SFTSV receptor LRP1 protein on an elisa plate, and compared with a standard virus strain Gn protein, the self-designed SFTSV Gn-8M has amino acid mutation of eight sites, has stronger combining capacity with a host cell receptor, and can be used for detecting the SFTSV. The kit disclosed by the invention has the characteristics of high safety, high efficiency, high flux, high specificity, high sensitivity, high stability and the like, and is suitable for large-scale rapid screening of the neutralizing antibody of the severe fever with thrombocytopenia syndrome virus.

The invention belongs to the field of veterinary biological products, and relates to a porcine reproductive and respiratory syndrome virus strain and application thereof. The invention particularly discloses a porcine reproductive and respiratory syndrome virus strain with a microbial preservation number of CGMCC (China General Microbiological Culture Collection Center) No.47095. The invention also discloses a vaccine composition prepared from the strain. After pigs are inoculated with the vaccine composition, the vaccine composition can resist challenge of a porcine reproductive and respiratory integrated virus SD strain and a porcine reproductive and respiratory integrated virus HuN4 strain, and has application prospects.

A coxsackievirus B4 strain and application thereof are disclosed. The strain is named KM140-G01 and is preserved in China Center for Type Culture Collection (CCTCC) on Jun. 18, 2023, and the preservation number is CCTCC NO: V202356, the preservation address is Wuhan University, China. The strain is a humanized coxsackievirus B4 wild type single purified strain, and has strong virus replication capacity, good genetic stability and immunogenicity; the strain can be applied to the development of human coxsackievirus B4 vaccine production strains, and is suitable for the development of attenuated coxsackievirus B4 vaccine and inactivated coxsackievirus B4 vaccine; the method can also be used for establishing an infection model on Vero cells and suckling mice, and is used for CVB4 infection and pathogenic mechanism research, CVB4 vaccine evaluation and antiviral drug screening.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain, which comprises a genome sequence shown in SEQ ID NO: 1. The attenuated strain comprises one or more genetic modifications of the sequence SEQ ID NO: 1, and the genetic modifications reduce the virulence of the strain.